Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ruben Niesvizky

Showing results (1-10 of 132) with videos related to

Pageof 14
Sort By:
Seminars in Oncology|May 31, 2003
Gallium nitrate in multiple myeloma: prolonged survival in a cohort of patients with advanced-stage diseaseRuben Niesvizky
Current Opinion in Oncology|September 7, 2017
Advances in immunotherapy in multiple myelomaLeora Boussi, Ruben Niesvizky
Seminars in Oncology|January 8, 2017
Deferring autologous stem cell transplantation for consolidation of minimal residual disease in multiple myelomaMarc Braunstein, Ruben Niesvizky
Leukemia Research|November 27, 2012
Sustained disease control in transplant-ineligible patients: the role of continuous therapyAntonio Palumbo, Ruben Niesvizky
Journal of the National Comprehensive Cancer Network : JNCCN|February 10, 2010
Complications of multiple myeloma therapy, part 2: risk reduction and management of venous thromboembolism, osteonecrosis of the jaw, renal complications, and anemiaRuben Niesvizky, Ashraf Z Badros
BMJ Case Reports|August 3, 2012
Bortezomib-induced thrombotic thrombocytopaenic purpuraNeha Mehta, Ashish Saxena, Ruben Niesvizky
Oncology (Williston Park, N.Y.)|June 4, 2010
Best practices in the management of newly diagnosed multiple myeloma patients who will not undergo transplantRuben Niesvizky, Morton Coleman, Tomer Mark
Critical Reviews in Oncology/Hematology|July 3, 2013
How lenalidomide is changing the treatment of patients with multiple myelomaMeletios A Dimopoulos, Evangelos Terpos, Ruben Niesvizky
Leukemia Research|April 3, 2014
Preclinical and clinical results with pomalidomide in the treatment of relapsed/refractory multiple myelomaTomer M Mark, Morton Coleman, Ruben Niesvizky
Expert Opinion on Investigational Drugs|December 5, 2008
Milatuzumab: a promising new agent for the treatment of lymphoid malignanciesTomer Mark, Peter Martin, John P Leonard, et al.
Pageof 14

Showing results (1-10 of 132) with videos related to

Sort By:
Pageof 14
Seminars in Oncology|May 31, 2003
Gallium nitrate in multiple myeloma: prolonged survival in a cohort of patients with advanced-stage diseaseRuben Niesvizky
Current Opinion in Oncology|September 7, 2017
Advances in immunotherapy in multiple myelomaLeora Boussi, Ruben Niesvizky
Seminars in Oncology|January 8, 2017
Deferring autologous stem cell transplantation for consolidation of minimal residual disease in multiple myelomaMarc Braunstein, Ruben Niesvizky
Leukemia Research|November 27, 2012
Sustained disease control in transplant-ineligible patients: the role of continuous therapyAntonio Palumbo, Ruben Niesvizky
Journal of the National Comprehensive Cancer Network : JNCCN|February 10, 2010
Complications of multiple myeloma therapy, part 2: risk reduction and management of venous thromboembolism, osteonecrosis of the jaw, renal complications, and anemiaRuben Niesvizky, Ashraf Z Badros
BMJ Case Reports|August 3, 2012
Bortezomib-induced thrombotic thrombocytopaenic purpuraNeha Mehta, Ashish Saxena, Ruben Niesvizky
Oncology (Williston Park, N.Y.)|June 4, 2010
Best practices in the management of newly diagnosed multiple myeloma patients who will not undergo transplantRuben Niesvizky, Morton Coleman, Tomer Mark
Critical Reviews in Oncology/Hematology|July 3, 2013
How lenalidomide is changing the treatment of patients with multiple myelomaMeletios A Dimopoulos, Evangelos Terpos, Ruben Niesvizky
Leukemia Research|April 3, 2014
Preclinical and clinical results with pomalidomide in the treatment of relapsed/refractory multiple myelomaTomer M Mark, Morton Coleman, Ruben Niesvizky
Expert Opinion on Investigational Drugs|December 5, 2008
Milatuzumab: a promising new agent for the treatment of lymphoid malignanciesTomer Mark, Peter Martin, John P Leonard, et al.
Pageof 14